Gloria Kayani is the Chief Executive Officer, with overall responsibility for creating, planning, implementing and integrating the strategic direction of CYTE.
Ms Kayani has nearly 25 years of experience in Pharmaceutical R&D, Medical Affairs and academic research, responsible for the strategic oversight and delivery of projects spanning all phases of clinical research. This includes 15 years in various leadership roles in clinical development at Glaxo SmithKline and Roche, managing cross functional and international clinical teams. She was a member of many clinical development teams for key Roche drugs. As Head of the Clinical Projects Group at Roche, she oversaw the management of 144 global randomised clinical trials, investigator initiated trials, early access programmes, non-interventional programmes and individual patient supply programmes.
For the last 9 years as Chief Operating Officer and Deputy Director of CYTE’s partner company, the Thrombosis Research Institute (TRI), Ms Kayani has been responsible for implementing and delivering TRI’s extensive, international clinical and science research programmes. She works closely with global experts and key opinion leaders in the thrombosis and cardiovascular medicine fields to ensure TRI delivers high quality research.